Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
AbstractSystemic amyloidoses are characterized by the unrelenting deposition of autologous proteins as highly ordered fibrils in target organs. The ensuing, potentially fatal organ dysfunction is the result of the combined damage caused by the proteotoxic effect of prefibrillar species and by the cytotoxicity and the structural alterations produced by the amyloid fibrils. Current therapy is focused on eliminating the amyloid protein, thus extinguishing the amyloid cascade at its origin. While this approach may end the cell damage caused by prefibrillar aggregates and prevent further amyloid accumulation, the noxious effect...
Source: BioDrugs - September 12, 2022 Category: Drugs & Pharmacology Source Type: research
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment
AbstractAcute respiratory distress syndrome (ARDS) is a severe respiratory disease associated with high morbidity and mortality in the clinic. In the face of limited treatment options for ARDS, extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) have recently shown promise. They regulate levels of growth factors, cytokines, and other internal therapeutic molecules. The possible therapeutic mechanisms of MSC-EVs i nclude anti-inflammatory, cell injury repair, alveolar fluid clearance, and microbe clearance. The potent therapeutic ability and biocompatibility of MSC-EVs have enabled them as an alternative ...
Source: BioDrugs - September 10, 2022 Category: Drugs & Pharmacology Source Type: research
Therapeutic siRNA: State-of-the-Art and Future Perspectives
This article reviews the knowledge on siRNA design and chemical modification, as well as issues related to siRNA delivery that may be addressed using different delivery systems. Details on the mode of action and clinical status of the various siRNA therapeutics are provided, before giving an outlook on issues regarding the future of siRNA drugs and on their potential as one emerging standard modality in pharmacotherapy. Notably, this may also cover otherwise un-druggable diseases, the definition of non-coding RNAs as targets, and novel concepts of personalized and combination treatment regimens. (Source: BioDrugs)
Source: BioDrugs - August 23, 2022 Category: Drugs & Pharmacology Source Type: research
Real-World Effects of Biologics on Renal Function in Psoriatic Patients: A Retrospective Study
ConclusionsBiologic treatments failed to improve but did not worsen renal function of psoriatic patients during a 2-year follow-up period. Diabetes is an important risk factor for the deterioration of renal function. (Source: BioDrugs)
Source: BioDrugs - August 22, 2022 Category: Drugs & Pharmacology Source Type: research
Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study
ConclusionsEducating physicians and pharmacists about biosimilars —including how biosimilarity is defined and operationalized, the structure of the biosimilar approval process, and how analytical data can ensure biosimilar safety and efficacy—will be important for reducing healthcare providers’ concerns and increasing biosimilar adoption in the US. (Source: BioDrugs)
Source: BioDrugs - August 13, 2022 Category: Drugs & Pharmacology Source Type: research
The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease
ConclusionThis study demonstrated a temporary yet discernible nocebo effect in the first 16 weeks following non-medical switching that was not sustained at week 32. Negative patient perceptions may be overcome by a patient-inclusive approach to non-medical switching in conjunction with close clinical follow-up and disease monitoring. (Source: BioDrugs)
Source: BioDrugs - August 12, 2022 Category: Drugs & Pharmacology Source Type: research
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
ConclusionWithin the limitations of this systematic review, available data suggests that biosimilar-to-biosimilar switching is a safe and effective clinical practice, although it is not covered by current health authority regulations or guidance. No reduction in effectiveness or increase in adverse events was detected in biosimilar-to-biosimilar switching studies conducted to date. (Source: BioDrugs)
Source: BioDrugs - July 26, 2022 Category: Drugs & Pharmacology Source Type: research
Plant-Derived Human Vaccines: Recent Developments
AbstractThe idea of producing vaccines in plants originated in the late 1980s. Initially, it was contemplated that this notion could facilitate the concept of edible vaccines, making them more cost effective and easily accessible. Initial studies on edible vaccines focussed on the use of a variety of different transgenic plant host species for the production of vaccine antigens. However, adequate expression levels of antigens, the difficulties predicted with administration of consistent doses, and regulatory rules required for growth of transgenic plants gave way to the development of vaccine candidates that could be purif...
Source: BioDrugs - July 12, 2022 Category: Drugs & Pharmacology Source Type: research
